Company Insights

AMWL customer relationships

Explore interactive graphBrowse insights index
AMWL customer relationship map

American Well (AMWL): customer relationships that shape the recovery story

American Well is an enterprise telehealth platform that sells recurring subscriptions to health plans, health systems and government clients, while supplementing revenue with professional services, hardware sales (Carepoint carts) and affiliated clinical services. Its monetization is driven by multi‑year contracts for the Amwell Platform, professional services and one‑time device sales, with material revenue concentration in a small number of large payers and growing validation from government awards. For deeper corporate relationship intelligence, visit https://nullexposure.com/.

Why the customer map matters for investors

American Well’s commercial model is subscription-first and enterprise-focused, which supports predictable revenue when contracts are long and non‑cancelable. However, the company also sells services and hardware that create shorter‑term revenue spikes and execution risk around implementations. The company’s disclosure that Elevance Health has been the single largest client (24–31% of revenue in recent years) underlines significant concentration risk that investors must price alongside the stability of recurring fees.

  • Contract posture: The company reports that typical contract terms are three years and many contracts are non‑cancelable over the contractual term, creating durable revenue recognition when renewals hold.
  • Revenue mix: Subscriptions (platform access) are the primary product, complemented by professional services and hardware sales.
  • Counterparties and geography: Customers include large enterprises, health plans, major health systems and government entities, with most revenue generated in the United States but stated international expansion opportunities.
  • Materiality signal: The filing explicitly identifies Elevance Health as the company’s largest customer by revenue across the 2023–2025 periods.

These company‑level signals point to a hybrid business model: predictable foundation revenue from subscriptions, combined with lumpy services and device income that can amplify headline swings.

Relationship map: every reported customer mention (short synopses)

Below are plain‑English summaries for every customer mention in the provided results, each tied to its reporting source.

  • Defense Health Agency (DHA) — American Well referenced its contract with the Defense Health Agency as a powerful validation on the Q4 2025 earnings call. (American Well 2025 Q4 earnings call, March 2026 transcript.)
  • SOAR — Management cited SOAR as a partner used to manage musculoskeletal (MSK) costs, noting integration as an example of platform extensibility. (American Well 2025 Q4 earnings call, March 2026 transcript.)
  • Avel eCare, LLC — The company announced the sale of its telepsychiatry business to Avel eCare for roughly $20.7 million as part of a strategic focus on Converge and profitability. (Quartz report on Amwell earnings, March 9, 2026.)
  • Avel eCare — Multiple business press reports reiterated the divestiture of Amwell Psychiatric Care to Avel eCare for about $21 million in cash to boost cash flow and concentrate on core platform growth. (QuiverQuant and MedicalDevice‑Network coverage, March 9, 2026.)
  • Elevance (Elevance Health) — Management disclosed a three‑year renewal with Elevance and noted that Elevance is the company’s largest client by revenue historically, reinforcing recurring revenue stability. (American Well 2025 Q4 earnings call; related SEC filing disclosures and press summaries, March 2026.)
  • Blue Cross Blue Shield of Florida — Amwell reported that Blue Cross Blue Shield of Florida went live on its platform in January, cited as part of over 15 payer contract activities that support recurring revenue. (American Well 2025 Q4 earnings call and press coverage, March 2026.)
  • Cleveland Clinic — Historical partnership: Amwell and Cleveland Clinic launched a joint venture (The Clinic) to deliver virtual care using Amwell’s technology, with revenue history and receivable disclosures tied to the relationship. (FierceHealthcare and Cleveland Clinic press release, 2019; referenced in company financial notes.)
  • Military Health System (MHS) — Press coverage previously reported Amwell’s selection to power the Military Health System’s digital‑first initiative, a precursor to later DHA/MHS contract mentions that catalyzed share movement. (RagingBull recap of 2023 reporting.)
  • U.S. Defense Health Agency — Separate news coverage reiterated selection by the U.S. Defense Health Agency (and partners) to support the Military Health System, underlining the government client theme. (RagingBull and other media, FY2023 coverage.)
  • Vida — Management named Vida as a digital companion partner used to address inappropriate GLP‑1 utilization, demonstrating Amwell’s strategy of integrating third‑party clinical solutions. (American Well 2025 Q4 earnings call, March 2026.)

What these relationships mean for revenue quality and risk

The relationship set delivers three investment takeaways:

  • Validation and diversification: Government contracts (DHA/MHS) and renewals with major payers like Elevance function as high‑quality validation that supports valuation if renewals persist. These contracts underpin the subscription backbone of revenue.
  • Concentration risk remains central. The explicit disclosure that Elevance accounted for roughly a quarter to a third of revenue in recent years is a clear materiality risk that heightens sensitivity to one counterparty’s procurement decisions and pricing leverage.
  • Operational complexity from mixed revenue streams. Hardware and services generate incremental revenue but increase implementation and execution risk; divesting the psychiatric care unit to Avel eCare signals management’s push to re‑focus on platform economics and cash generation (Avel eCare sale reported March 2026).

For investors wanting a structured view of customer dependencies, these relationship threads are the primary drivers of near‑term upside (renewals, government wins) and downside (concentration, integration execution).

If you want a concise, exportable mapping of these client relationships for portfolio diligence, visit https://nullexposure.com/ to learn how we synthesize customer signals.

Actionable guidance for operators and investors

  • Monitor the Elevance renewal cadence and contract terms closely; any decline in Elevance usage would materially affect revenue given the historical share.
  • Watch delivery milestones and go‑lives for DHA/MHS and Blue Cross Blue Shield of Florida as indicators that government and payer wins are converting into recurring revenue.
  • Track how Amwell redeploys proceeds from the Avel eCare sale to support the Converge platform and margin expansion; that divestiture is management’s explicit lever to improve cash flow.

For practical customer‑level alerts and deeper relationship analytics on AMWL, go to https://nullexposure.com/ — the fastest way to align commercial signals with investment models.

American Well’s story is straightforward: a subscription platform with high‑value enterprise clients and government validation, balanced against real concentration and execution risks. Investors should weight the stability of multi‑year contracts and payer renewals against single‑client exposure and the company’s progress integrating partners and converting one‑time wins into durable recurring revenue.